Delayed-Onset Filler Nodules: Practitioner Guide | Two Face Aesthetics

A patient returns to your clinic with a lump or swelling in an area treated with dermal filler months ago.

The original procedure was uneventful. The filler settled normally. The patient may have experienced no problems whatsoever for weeks or months.

Now something has changed.

What do you do next?

Delayed-onset nodules (DONs) are a recognised complication following dermal filler treatment, but a delayed nodule is a clinical presentation rather than a single diagnosis. Different underlying causes require different approaches to investigation and management.

There is also an emerging consideration for aesthetic practitioners.

Recent published reports have described delayed reactions at previous aesthetic injection sites in patients receiving incretin-based medicines used in weight management, including semaglutide and tirzepatide.

The available evidence does not establish that GLP-1 or related medicines cause delayed filler nodules. However, increasing use of these medicines raises an important practical question:

Should GLP-1/GIP treatment now form part of the clinical history when assessing a patient with a delayed filler complication?

What Are Delayed-Onset Filler Nodules?

Delayed-onset nodules are lumps, areas of induration, swelling or inflammatory lesions that develop after the expected immediate recovery period following dermal filler treatment.

They may occur weeks or months after injection, including after the treatment area appeared to have completely settled.

Importantly, “delayed-onset nodule” does not tell us what has caused it.

The differential diagnosis can include:

non-inflammatory product-related nodules;
delayed inflammatory or immune-mediated reactions;
infection;
biofilm-associated processes;
granulomatous reactions; and
other local tissue responses.

Establishing the likely underlying process matters because management can differ considerably.

A painless, non-inflammatory nodule is not the same clinical problem as a painful, erythematous and fluctuant lesion.

For broader background on filler types and selection, see our guide to choosing the right dermal filler.

A Patient Presents With a Delayed Filler Nodule: What Should You Do First?

The initial response should not automatically be: “Dissolve it.”

Nor should every swollen or erythematous nodule immediately be assumed to represent infection.

The practitioner needs to establish what has happened, what was originally injected and what may have changed since treatment.

Establish What Was Injected

Where possible, determine:

filler brand and product;
whether the material was hyaluronic acid (HA), calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA) or another material;
treatment date;
anatomical location;
amount injected;
injection technique and plane where known;
previous treatment to the same area; and
other injectable treatments performed at the same or nearby sites.

Where another practitioner or clinic performed the original treatment, obtaining the original treatment record may be valuable.

The material is particularly important. HA filler may potentially be degraded using hyaluronidase where clinically appropriate. CaHA, PLLA and other non-HA products cannot simply be dissolved using the same approach.

Our Restylane vs Juvederm comparison provides further context on commonly used HA filler families.

Establish the Timeline

Ask when the patient first noticed the problem and how it developed.

Was the treatment area completely normal for several months before becoming swollen? Did symptoms develop suddenly or gradually? Has the patient experienced recurrent episodes? Have several previously treated areas become symptomatic at approximately the same time?

Chronology can provide important clues about the nature of the complication.

Is the Nodule Inflammatory or Non-Inflammatory?

Examine the patient rather than simply treating the word “nodule”.

Relevant clinical features can include:

erythema;
warmth;
pain or tenderness;
swelling;
induration;
fluctuance;
discharge;
multiple nodules;
recurrent inflammatory episodes; and
systemic symptoms.

A small, painless and non-inflammatory lump presents a very different clinical picture from a hot, painful, erythematous and fluctuant lesion.

Where infection or abscess is suspected, the management pathway changes substantially.

Don’t Stop the History at the Filler Appointment

One of the most important parts of assessing a delayed complication is establishing what happened after the original filler treatment.

Ask about intervening events including:

illness or infection;
dental treatment;
vaccination;
newly commenced medication;
medication dose changes;
inflammatory or immune illness; and
weight-management medication.

The US Food and Drug Administration has noted reports of inflammation around dermal filler sites following viral or bacterial illnesses or infections, vaccinations and dental procedures.

The important principle is therefore already recognised: a previously treated filler site can, in some circumstances, become involved in a later inflammatory event.

And another potential trigger is now attracting attention.

GLP-1 Medicines and Delayed Filler Reactions: What Is the Emerging Evidence?

GLP-1 and related incretin-based medicines have transformed medical weight management.

Medicines containing semaglutide and tirzepatide are now used by a rapidly growing patient population, including many people who have previously received aesthetic injectable treatments.

Emerging published literature has begun to describe delayed reactions involving previous aesthetic injection sites following initiation of these medicines.

A 2026 report in JAAD Case Reports described facial nodules developing at previous hyaluronic acid, calcium hydroxylapatite and botulinum toxin injection sites following initiation of compounded tirzepatide.

The temporal pattern was particularly noteworthy. The report described cessation of new nodules following discontinuation of tirzepatide, followed by recurrence after rechallenge and dose escalation.

That makes the case scientifically interesting. It does not prove that tirzepatide caused the reaction.

Published literature has also described delayed facial oedema following HA filler that appeared and worsened after semaglutide (Ozempic) was started.

These observations represent an emerging clinical signal, not evidence of an established GLP-1 class effect.

Do Semaglutide or Tirzepatide Cause Delayed Filler Nodules?

Based on the evidence currently available: we cannot say that they do.

Case reports are valuable because they can identify unusual or previously unrecognised clinical patterns.

They cannot establish:

how frequently an event occurs;
whether a medicine caused the event;
whether there is a class effect;
which patients might be susceptible;
whether dosage or duration influences risk; or
whether the association occurred coincidentally.

Large numbers of patients now use incretin-based medicines, while dermal filler treatment is also common. Some patients will inevitably have both exposures without one causing the other.

The appropriate conclusion is therefore not: “GLP-1 medicines cause filler nodules.”

It is: “There is sufficient emerging evidence for GLP-1/GIP medication to be worth considering as part of the wider clinical history when investigating a delayed filler reaction.”

Could Infection or Biofilm Be Involved?

This is an important part of the differential diagnosis.

A delayed inflammatory nodule is not automatically an infection. Equally, practitioners should not assume that every delayed reaction is sterile inflammation.

Infectious and potentially biofilm-associated processes have long formed part of the differential diagnosis of delayed filler complications.

Particular attention should be paid to presentations involving increasing pain, significant erythema, warmth, tenderness, progressive swelling, fluctuance, discharge or systemic illness.

A suspected abscess requires a very different approach from an uncomplicated non-inflammatory HA nodule.

The objective should therefore be to establish the likely pathology before reflexively attempting to suppress inflammation or dissolve filler.

Where Can Ultrasound Help?

Ultrasound is becoming an increasingly useful tool in aesthetic complication assessment.

Where available and clinically appropriate, imaging may help establish:

the location of previously injected filler;
the relationship between filler and the lesion;
whether a discrete collection is present;
characteristics of the affected tissue; and
whether further intervention may be appropriate.

Ultrasound is not necessary for every delayed nodule. However, in complex, persistent or diagnostically uncertain presentations, it can provide information that clinical examination alone may not.

Where infection is suspected, appropriate microbiological investigation may also be required.

Should You Use Hyaluronidase?

Hyaluronidase can degrade hyaluronic acid filler and may therefore form part of the management of selected HA-related complications.

But: delayed nodule ≠ automatically inject hyaluronidase.

Before deciding upon treatment, consider: What material is actually present? Is the lesion inflammatory or non-inflammatory? Is infection reasonably suspected? Could there be an abscess or collection? Would imaging or further investigation change the management plan? And fundamentally: is the filler actually hyaluronic acid?

Hyaluronidase cannot simply dissolve CaHA or PLLA.

What About Antibiotics or Corticosteroids?

Treatment should follow clinical assessment and the suspected pathology.

Where infection is suspected, appropriate antimicrobial treatment may be required. A collection or abscess may also require drainage, microbiological investigation and further medical management rather than medication alone.

Conversely, indiscriminate antibiotic prescribing for every delayed inflammatory reaction is inconsistent with good antimicrobial stewardship.

Corticosteroids also require careful consideration. Suppressing inflammation without adequately considering an underlying infection may be inappropriate and potentially harmful.

Prescription medicines should only be prescribed following appropriate clinical assessment by an authorised prescriber and used within the practitioner’s competence and applicable professional standards.

When Should You Escalate or Refer?

Good complication management includes recognising when the patient requires expertise beyond your own practice.

Escalation or referral should be considered where:

the diagnosis remains uncertain;
symptoms are severe or progressive;
infection or abscess is suspected;
systemic symptoms are present;
the original filler product is unknown;
the presentation falls outside the practitioner’s competence;
initial management has failed;
imaging or specialist investigation is required; or
multidisciplinary input may improve patient management.

Knowing when not to treat is part of knowing how to manage a complication.

Should a Patient Stop Semaglutide or Tirzepatide?

Practitioners should not automatically advise patients to discontinue prescribed medication because a delayed filler reaction has developed.

Decisions about semaglutide, tirzepatide or another prescribed medicine should involve the healthcare professional responsible for prescribing and monitoring that treatment, alongside the clinician managing the aesthetic complication.

The discontinuation, rechallenge and dose-escalation pattern described in the 2026 tirzepatide case is valuable from a pharmacovigilance perspective. It should not be converted into a general recommendation that patients experiencing filler reactions should stop their medication.

Should Patients Taking GLP-1 Medicines Avoid Dermal Fillers?

There is currently insufficient evidence to conclude that patients using semaglutide, tirzepatide or related medicines should routinely avoid dermal filler treatment.

Instead, practitioners should take an appropriate medical and medication history and assess each patient’s suitability and risk individually.

Patients should also understand the importance of informing the clinician assessing a complication about medication started after their original filler appointment.

Should GLP-1 Treatment Now Appear on Aesthetic Consultation Forms?

The growing prevalence of medical weight-management treatment makes this worth considering.

Medication history should already form part of an appropriate aesthetic consultation. However, the emerging literature provides another reason to ensure that new medicines and recent dose changes are specifically considered when investigating delayed complications.

A patient may have received filler twelve months ago and commenced weight-management treatment only recently. The original filler record cannot capture a medication the patient wasn’t taking at the time. Updating the medical history therefore matters.

Delayed-Onset Filler Nodule: Practitioner Checklist

Filler: What product was injected, where and when?
Presentation: Is the lesion inflammatory or non-inflammatory?
Timeline: When did symptoms begin and how have they progressed?
Potential triggers: Has there been recent illness, infection, vaccination or dental treatment?
Medication: Have any medicines recently been started, stopped or changed, including semaglutide, tirzepatide or other incretin-based treatment?
Infection: Are pain, heat, erythema, fluctuance, discharge or systemic symptoms present?
Investigation: Would ultrasound, microbiology or another investigation change management?
Filler material: Is this HA filler potentially amenable to hyaluronidase, or a different material requiring another approach?
Competence: Can the complication safely be managed within your own scope of practice?
Escalation: Does the patient require referral, specialist assessment or multidisciplinary input?

The Key Message for UK Aesthetic Practitioners

Delayed-onset filler nodules are not new.

What is new is the emerging literature describing delayed reactions at previous aesthetic injection sites in patients using GLP-1 and related incretin-based medicines.

At present, we do not know whether these medicines have a causal relationship with delayed filler reactions. And that uncertainty is exactly why practitioners should avoid jumping to conclusions in either direction.

A patient presenting with a delayed nodule requires: history → examination → differential diagnosis → investigation where appropriate → management or escalation.

Not simply an assumption that the filler needs dissolving.

As the use of semaglutide, tirzepatide and related medicines continues to increase, medication initiation and dose changes may become an increasingly relevant part of that history.

The most useful question for practitioners today is therefore not: “Do GLP-1 medicines cause filler nodules?” Current evidence cannot answer that.

Instead, ask: “If a patient walks into my clinic tomorrow with a delayed filler complication, would I know what to look for, what questions to ask and when to escalate?”

That is the question every aesthetic practitioner should be able to answer.

References and Further Reading

The evidence concerning GLP-1/GIP medicines and previous aesthetic injectable sites is evolving. Practitioners should refer to current literature and relevant clinical guidance when assessing individual cases.

Medical disclaimer: This article is intended for general educational information for healthcare and aesthetic professionals. It does not establish that semaglutide, tirzepatide, GLP-1 or related medicines cause delayed filler reactions. It does not replace individual clinical assessment, diagnosis, prescribing decisions or specialist advice. Practitioners should work within their competence and applicable professional standards. Patients with suspected complications should receive appropriate clinical assessment.

Delayed-Onset Filler Nodules: Would You Know How to Manage This in Your Practice?